This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Annals of Hematology Open Access 28 April 2015
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia – Berlin – Frankfurt – Munster 93. J Clin Oncol 2001; 19: 2705–2713.
Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T . Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384–4393.
Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 2001; 97: 3727–3732.
Hann IM, Webb DK, Gibson BE, Harrison CJ . MRC trials in childhood acute myeloid leukaemia. Ann Hematol 2004; 83 (Suppl 1): S108–S112.
Stevens RF, Hann IM, Wheatley K, Gray RG . Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101: 130–140.
Dastugue N, Lafage-Pochitaloff M, Pages MP, Radford I, Bastard C, Talmant P et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 2002; 100: 618–626.
Duchayne E, Fenneteau O, Pages MP, Sainty D, Arnoulet C, Dastugue N et al. Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Francais d’Hematologie Cellulaire (GFHC). Leuk Lymphoma 2003; 44: 49–58.
Garderet L, Labopin M, Gorin NC, Polge E, Baruchel A, Meloni G et al. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2005; 105: 405–409.
Krance RA, Hurwitz CA, Head DR, Raimondi SC, Behm FG, Crews KR et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001; 19: 2804–2811.
This work was supported by grants from the ‘Deutsche Krebshilfe’ (UC, JR), the ‘Deutsche José Carreras Leukämie Stiftung’ (UC, DR) and the ‘Leukemia & Lymphoma Society’ (DR, CL).
About this article
Cite this article
Reinhardt, D., Diekamp, S., Langebrake, C. et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia 19, 1495–1496 (2005). https://doi.org/10.1038/sj.leu.2403815
This article is cited by
Annals of Hematology (2015)
NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern
Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421